WO2006046766A1 - 心不全治療のための遺伝子治療 - Google Patents
心不全治療のための遺伝子治療 Download PDFInfo
- Publication number
- WO2006046766A1 WO2006046766A1 PCT/JP2005/020163 JP2005020163W WO2006046766A1 WO 2006046766 A1 WO2006046766 A1 WO 2006046766A1 JP 2005020163 W JP2005020163 W JP 2005020163W WO 2006046766 A1 WO2006046766 A1 WO 2006046766A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hgf
- growth factor
- vad
- myocardium
- heart
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention is gene therapy for treating heart failure or a medicament thereof.
- the left ventricular assist device (LVAD) is frequently used to assist blood circulation until a heart transplant can be performed.
- Hepatocyte growth factor is mediated by c-Met, which is a specific receptor in various cells including muscle cells.
- HGF has an inhibitory effect on fibrosis and apoptosis in the myocardium [8-10].
- HGF may have a beneficial effect on reducing the remodeling process in heart failure [13, 14].
- HGF gene transfer may enable “bridge to recovery” for LVAD-assisted cardiac disorders.
- W001 / 026694 discloses a method for noninvasive administration of HGF gene encapsulated in Sendai virus (HVJ) -ribosome for cardiac function repair to the site of myocardial lesions.
- HVJ Sendai virus
- VAD virtual artificial heart
- the present invention relates to the following.
- AZA Angiogenic site force infusion for the treatment of acute myocardial infarction (AMI), idiopathic cardiomyopathy (ICM), dilated cardiomyopathy (DCM) or heart failure administered in combination with an auxiliary artificial heart (VAD)
- a drug consisting of a gene that codes
- Figure 1 is a photograph showing an animal model and experimental design for heart failure.
- A The left anterior descending branch (LAD) of an adult goat heart was ligated to produce myocardial infarction, and a plasmid encoding hHGF cDNA or] 3-galatasidase was administered directly into the myocardium.
- Biventricular assist devices are attached to a heart failure goat.
- Figure 2 shows a graph comparing the VAD support rate (A) and a graph comparing the native cardiac output of the HGF group (mouth) and the control group (O) in this experiment (B).
- Fig. 3 is a diagram comparing wall contractility with% left ventricular diameter shortening rate (% FS) calculated by sonomicrometry.
- the HGF group is indicated by mouth, and the control group is indicated by ⁇ .
- Figure 4 shows the hemodynamic changes after removing VAD.
- Heart rate (n HR), systemic blood pressure (B, mean AoP), mixed venous oxygen saturation (C, Sv02), pulmonary pulse pressure (D, mean PAP), native cardiac output (E, CO) and left ventricular end-diastolic diameter (F, LVDd) were measured.
- B systemic blood pressure
- C mixed venous oxygen saturation
- D pulmonary pulse pressure
- E native cardiac output
- F left ventricular end-diastolic diameter
- Figure 5 is a photograph showing the cardiac histological findings 4 weeks after gene transfer.
- A, C, ⁇ and G are in the HGF group.
- ⁇ , D, F and ⁇ are control groups.
- Figure 6 is a graph showing the results of evaluation of histological findings.
- the present invention also includes the following in detail.
- HGF hepatocyte growth factor
- VEGF vascular endothelial growth factor
- FGF fibroblast growth factor
- EGF epidermal growth factor
- NGF nerve growth factor
- TGF transforming growth factor
- PDGF platelet-derived growth factor
- IGF insulin-like growth factor
- the angiogenesis site force-in is HGF, (1) or (2)
- the angiogenesis site force-in is directly administered to the myocardium, (1) to (4) (6)
- the angiogenesis site force in is administered to a plurality of locations of the myocardium, (1) to (5) the medicament according to any one of
- the myocardium is an ischemic site in the left ventricular wall, (1) to (6)
- the VAD is a left ventricular assist device (LVAD).
- the pharmaceutical according to any one of (1) to (7).
- LVAD left ventricular assist device
- HGF hepatocyte growth factor
- gene therapy using HGF-cDNA plasmids may increase the possibility of “Bridge to Recovery”.
- HGF gene therapy using LVAD in a heart failure goat. Specifically, six adult goats (56-65 kg) were prepared for cardiac injury by coronary artery ligation and VAD was attached.
- HGF-cDNA plasmid (2. Omg) was administered intramyocardially.
- the control group (n 3) was similarly administered with [3-caractosidase 'plasmid].
- VAD was removed from all goats.
- Myocardium transfected with hHGF-cDNA contained human HGF protein at a level of 1.0 ⁇ 0.3 ng / tissue (g) 3 days after introduction.
- the HGF group showed good hemodynamics, while the control group showed worsening.
- % The left ventricular shortening rate was significantly higher in the HGF group compared to the control group (HGF vs. control, 37. 9 ⁇ 1.7% vs.
- human HGF represented by SEQ ID NO: 1 was inserted into the Not I site of pUC—SRa expression vector plasmid.
- hHGF cDNA is regulated under the control of an SR promoter composed of the simian virus 40 polyadenylation sequence.
- Purified plasmid containing 2000 ⁇ g of hHGF-c DNA was reconstituted in 2. OmL of sterile saline, and injected directly into 10 locations of the myocardium using a 2.5 mL syringe and 3 ° gauge needle.
- the hHGF concentration in the heart was determined by enzyme-linked immunosorbent assay (EL I SA) using an anti-human HGF antibody (Immunological Society, Tokyo, Japan).
- Antibodies against hHGF react only with hHGF and not with captive HGF. Serum hHGF levels were also evaluated using the same EL ISA device on days 1, 3, 5, 7, 14, 28 after cDNA injection.
- a left fifth intercostal thoracotomy was performed under general anesthesia with isoflurane and nitrous oxide.
- a polyethylene catheter was inserted into the thoracic aorta via the left carotid artery for systemic blood pressure (BP) measurement and into the left jugular vein for intravenous injection.
- BP systemic blood pressure
- a fiber optic pulmonary artery catheter (Ox i me trix; Ab bott Critica 1 Ca resyst ems, North Chicago, Illinois) is placed in the pulmonary artery to deliver mixed venous oxygen consumption (S v02) and pulmonary artery pressure (PAP) Mixed I tried to make it.
- S v02 mixed venous oxygen consumption
- PAP pulmonary artery pressure
- Heart rate (HR) was continuously monitored by electrocardiogram.
- an electromagnetic flow meter (MF-2100; Nihon Kohden, Tokyo, Japan) was placed in the ascending aorta and the LVAD was placed in the flow output neuron.
- the aortic blood flow was used as an index of the native heart rate mass, and the VAD assist rate was calculated as follows.
- VAD auxiliary rate (%) Bypass flow (LZ min) Z [Aortic flow (L / min) + Bypass flow (LZ min)]
- a dysfunctional heart was created by ligating the left anterior descending coronary artery (LAD) to the distal side of its first oblique branch ( Figure 1, A).
- LAD left anterior descending coronary artery
- LVAD Toyobo, Osaka, Japan
- RVAD Toyobo, Osaka, Japan
- the goats were randomly divided into two groups.
- ⁇ Rufalin 'sodium was administered to the target at an international standard ratio ranging from 2.5 to 3.5.
- the LV dimensions at the end of myocardial diastole (LVDd) and at the end of myocardial systole (LVD s) were determined by LV P measured simultaneously.
- the LV shortening percentage (% FS) was calculated as follows.
- % F S (%) (LVDd— LVD s) / L VD d X 100
- VAD stop test At four weeks after gene transfection, an attempt was made to pull all goats away from BVAD.
- the heart was cut into 5 pieces along the short axis, and LV myocardial specimens were fixed in 10% buffered hormone and embedded in paraffin.
- the percentage of the area occupied by fibrosis in the border region adjacent to the infarct was measured on a field chosen at 10 random, and the results were expressed as a percentage of fibrosis.
- the immunohistological color of the antigen associated with von Willebrand factor was performed according to a modified protocol.
- EPOS-conjugated antibodies against antigens related to von Willebrand factor linked to HRP were used as primary anti-anti.
- Stained vascular endothelial cells were counted as vessel density under a 200 ⁇ light microscope using at least 10 randomly selected fields per section.
- Results were expressed as the number of blood vessels per mm 2 .
- the hHGF protein content in the myocardial sample obtained from the region injected with cDNA was measured by EL ISA assay.
- Myocardium transfected with hHGF-c DNA contained a high concentration of hHGF protein of 1 ⁇ 0 ⁇ 0 ⁇ 3 ng per gram of tissue on the third day of transfection.
- Native cardiac output decreased by about 20 or 3 OmL / kg / min.
- the heart rate output in the HGF group was significantly higher than that in the subject group (compared to 85.0 ⁇ 1.4 mLZkg / min in the HGF group). 64.6 ⁇ 6 OmL / kg / min in the control group, p ⁇ 0.01; FIG. 2, 8).
- % FS was recovered in two groups after gene transfection:% FS However, the improvement in% FS in the HGF group was much greater than in the control group.
- VAD ⁇ stop test j '' (Fig. 4) was performed ⁇ In the load state after turning off BVAD, HR in the control group steadily increased, BP steady However, in the HGF group, these parameters remained stable and did not deteriorate.
- the cardiomyocytes in the control group are intensified.
- the blood vessel density was much higher in the HGF group compared to the control group (in the HGF group 35.2 ⁇ 2.1 vessels per field of view, compared to 24 vessels per quarter in the control group. 5 ⁇ 2. 7 p, 0.05; Figure 6, C).
- VAD not only assists systemic circulation, but also provides an optimal environment for myocardial recovery with ventricular unloading [2-5, 21-23].
- V A D provides sufficient time and appropriate conditions for myocardial regeneration, and regenerative treatment promotes myocardial recovery in the damaged heart and increases “bridge to recovery”.
- HGF is a powerful angiogenic factor and we have started its clinical application for patients with obstructive arteriosclerosis at Osaka University Hospital [24].
- HGF is not only an angiogenic factor, but also exhibits a variety of physiological leprosy activities including antifibrotic and cardioregressive activities [6-9, 25, 26]
- HGF must be advantageous in promoting myocardial regeneration.
- the progression of cardiac remodeling accompanied by decreased cardiac function during the chronic phase of myocardial infarction is involved not only in apoptosis of cardiomyocytes but also in interstitial fibrosis.
- fibrosis far away from the infarct region is considered to be a major factor in ventricular remodeling in ischemic cardiomyopathy.
- angiogenesis is induced and fibrosis is suppressed in the peri-infarct region by HGF gene transfection.
- Transforming growth factor ⁇ and angiotensin I I force are believed to play an important role in the pathology of fibrosis [28-30].
- HGF-cDNA plasmid delivers enough HGF locally and continuously into the wall to enhance angiogenesis and cardiac function in the infarcted myocardium even when administered directly. This is because [6-8, 24, 25]. Forces that natural HGF may play an important role as a cardioprotective factor Natural HGF is insufficient to attenuate cardiac remodeling in this experiment.
- the plasmid gene transformation also supports the cardioprotective function of native HGF, so that even lesser amounts of continuously expressed protein induce angiogenesis and subsequent recovery of local cardiac function. Sufficient to support [13, 14].
- HGF functions as a paracrine growth factor, and production of HGF by administration of the HGF-c DNA plasmid into the myocardium lasts for about 14 days.
- the present invention is the first report demonstrating the efficacy of regenerative treatment in an injured heart under LV AD, and the protocol of this study can be used as one of the new treatment strategies for severe heart failure.
- a method to compensate for the amount of contraction such as cellular cardiomyoplasty, may be necessary to enhance the therapeutic effect.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/665,007 US20090012498A1 (en) | 2004-10-29 | 2005-10-27 | Gene therapy for treatment of heart failure |
EP05800033A EP1810696A4 (en) | 2004-10-29 | 2005-10-27 | GENE THERAPY FOR THE TREATMENT OF HEART FAILURE |
JP2006542411A JPWO2006046766A1 (ja) | 2004-10-29 | 2005-10-27 | 心不全治療のための遺伝子治療 |
CA002582143A CA2582143A1 (en) | 2004-10-29 | 2005-10-27 | Gene therapy for treatment of heart failure |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004317329 | 2004-10-29 | ||
JP2004-317329 | 2004-10-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006046766A1 true WO2006046766A1 (ja) | 2006-05-04 |
Family
ID=36227988
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/020163 WO2006046766A1 (ja) | 2004-10-29 | 2005-10-27 | 心不全治療のための遺伝子治療 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20090012498A1 (ja) |
EP (1) | EP1810696A4 (ja) |
JP (1) | JPWO2006046766A1 (ja) |
CA (1) | CA2582143A1 (ja) |
WO (1) | WO2006046766A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009039217A1 (en) * | 2007-09-20 | 2009-03-26 | Cardium Therapeutics, Inc. | Medicaments for the treatment of coronary syndromes |
JP2009082229A (ja) * | 2007-09-27 | 2009-04-23 | Terumo Corp | 細胞移植機能を伴う心臓アシストシステム |
WO2016112049A1 (en) * | 2015-01-06 | 2016-07-14 | Cardiovascular Biotherapeutics, Inc. | Angiogenic treatment of ischemic heart disease |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2230819C (en) * | 1995-08-29 | 2009-04-14 | Sumitomo Pharmaceuticals Co., Ltd. | Medicament comprising hgf gene |
CN101085363A (zh) * | 1999-10-08 | 2007-12-12 | 安增子摩祺株式会社 | 肝细胞生长因子基因的应用 |
JP2005097118A (ja) * | 2000-07-18 | 2005-04-14 | Yoshiki Sawa | Hgf遺伝子からなる細胞移植定着促進剤 |
WO2004050126A2 (en) * | 2002-12-02 | 2004-06-17 | Anges Mg, Inc. | Compositions for treating or preventing angiogenesis-dependent symptoms |
-
2005
- 2005-10-27 EP EP05800033A patent/EP1810696A4/en not_active Withdrawn
- 2005-10-27 US US11/665,007 patent/US20090012498A1/en not_active Abandoned
- 2005-10-27 JP JP2006542411A patent/JPWO2006046766A1/ja active Pending
- 2005-10-27 WO PCT/JP2005/020163 patent/WO2006046766A1/ja active Application Filing
- 2005-10-27 CA CA002582143A patent/CA2582143A1/en not_active Abandoned
Non-Patent Citations (9)
Title |
---|
KOIKE H. ET AL.: "6. Kekkan Shinsei to Saisei Iryo", ANNUAL REVIEW JUNKANKI 2002, 2002, pages 38 - 44, XP003006810 * |
KOIKE H. ET AL.: "Kekkan Kino no Saisei", KAGAKU KOGYO, December 2002 (2002-12-01), pages 925 - 929, XP003006811 * |
MATSUDA H.: "Jusho Shinfuzen Chiryo ni Okeru Hojo Jinko Shinzo no Yakuwari", THE JAPANESE JOURNAL OF ARTIFICIAL ORGANS, vol. 32, no. 1, 2003, pages 7 - 12, XP003006816 * |
MITAMURA Y.: "Jinko Shinzo (Kiso)", THE JAPANESE JOURNAL OF ARTIFICIAL ORGANS, vol. 31, no. 3, 2003, pages 75 - 78, XP003006817 * |
SAWA Y.: "2. Shinkin ni Okeru Saibo Chiryo", EXPERIMENTAL MEDICINE, vol. 21, no. 8, 2003, pages 1116 - 1121, XP003006814 * |
SAWA Y.: "Junkanki Geka ni Okeru Idenshi Chiryo", IGAKU NO AYUMI, vol. 192, no. 3, 2000, pages 229 - 232, XP003006813 * |
SAWA Y.: "Kyoketsu Shinkin ni Taisuru Idenshi Chiryo to Rinsho Kogaku", CLINICAL ENGINEERING, vol. 14, no. 2, 2003, pages 167 - 171, XP003006815 * |
SAWA Y.: "Zoki Fuzen Chiryo no Atarashii Hoko Jusho Shinfuzen ni Taisuru Shinkin Saisei Chiryo", GENDAI IRYO, vol. 33, 2001, pages 2928 - 2932, XP003006812 * |
See also references of EP1810696A4 * |
Also Published As
Publication number | Publication date |
---|---|
US20090012498A1 (en) | 2009-01-08 |
CA2582143A1 (en) | 2006-05-04 |
EP1810696A1 (en) | 2007-07-25 |
EP1810696A4 (en) | 2008-03-05 |
JPWO2006046766A1 (ja) | 2008-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Losordo et al. | Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia | |
Rufaihah et al. | Dual delivery of VEGF and ANG-1 in ischemic hearts using an injectable hydrogel | |
TWI805565B (zh) | 心肌病、陳舊性心肌梗塞及慢性心臟衰竭的治療藥物 | |
US20100280493A1 (en) | Methods and Systems for Treating Injured Cardiac Tissue | |
Sellke et al. | Angiogenesis in cardiovascular disease: current status and therapeutic potential | |
US20230285507A1 (en) | Compositions and methods for cardiac tissue repair | |
EP1948246A2 (en) | Stem cell factor therapy for tissue injury | |
Siltanen et al. | Bcl-2 improves myoblast sheet therapy in rat chronic heart failure | |
US20080089867A1 (en) | Method of increasing retention, survival and proliferation of transplanted cells in vivo | |
Fukuda et al. | Angiogenic strategy for human ischemic heart disease: brief overview | |
WO2006046766A1 (ja) | 心不全治療のための遺伝子治療 | |
Shirakawa et al. | Gene transfection with human hepatocyte growth factor complementary DNA plasmids attenuates cardiac remodeling after acute myocardial infarction in goat hearts implanted with ventricular assist devices | |
EA019099B1 (ru) | Способ направленной доставки трансгена в миокард пациента с ишемией миокарда | |
JP2009530412A (ja) | 損傷心臓組織治療の方法と方式 | |
JP2005035945A (ja) | 組織再生複合療法 | |
ES2566344T3 (es) | VEGF-A para inducir regeneración del tejido miocárdico | |
JP4111950B2 (ja) | 自家骨髄の心筋内注射 | |
Wakabayashi et al. | Clinical experience with heparinless venoarterial bypass without oxygenation for the treatment of acute cardiogenic shock | |
Shao et al. | Therapeutic angiogenesis with autologous hepatic tissue implantation and omental wrapping | |
Takewa et al. | Gene Therapy for Angiogenesis under a Ventricular Assist System | |
AU2018213671B2 (en) | Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure | |
RU2795320C2 (ru) | Терапевтическое средство для лечения кардиомиопатии, перенесенного инфаркта миокарда и хронической сердечной недостаточности | |
Zhou et al. | Targeted Delivery of Insulin-Like Growth Factor-1 Improves Stem Cell Therapy in A Rat Myocardial Infarction Model | |
Merentie | Cardiological studies in mice: special emphasis on gene therapy, imaging and ECG findings | |
Sidebotham | Extracorporeal Membrane Oxygenation Clinical Dilemmas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MD MG MK MN MW MX MZ NA NG NO NZ OM PG PH PL PT RO RU SC SD SG SK SL SM SY TJ TM TN TR TT TZ UG US UZ VC VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IS IT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006542411 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2582143 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11665007 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005800033 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005800033 Country of ref document: EP |